Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (161-170 of 189) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens, Justin M Asquith, James M Leatherman, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
SITC strategic vision: prevention, premalignant immunity, host and environmental factorsSasha E Stanton, Kristin G Anderson, Tullia C Bruno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2017
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid TumorsJeffrey S Miller, Chihiro Morishima, Douglas G McNeel, et al.
NPJ Breast Cancer|November 9, 2019
If we build it they will come: targeting the immune response to breast cancerMargaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, et al.
Nature Medicine|August 24, 2004
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalTyler J Curiel, George Coukos, Linhua Zou, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancerSasha E Stanton, Denise L Cecil, Howard H Bailey, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.
Journal for Immunotherapy of Cancer|June 9, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancerMary L Disis, Sarah F Adams, Jyoti Bajpai, et al.
Cancer Research|April 5, 2017
Precancer Atlas to Drive Precision Prevention TrialsAvrum Spira, Matthew B Yurgelun, Ludmil Alexandrov, et al.
Cancer Immunology Research|August 14, 2014
Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinomaKelly G Paulson, Andrew Tegeder, Christoph Willmes, et al.
Pageof 19

Showing results (161-170 of 189) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens, Justin M Asquith, James M Leatherman, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
SITC strategic vision: prevention, premalignant immunity, host and environmental factorsSasha E Stanton, Kristin G Anderson, Tullia C Bruno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2017
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid TumorsJeffrey S Miller, Chihiro Morishima, Douglas G McNeel, et al.
NPJ Breast Cancer|November 9, 2019
If we build it they will come: targeting the immune response to breast cancerMargaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, et al.
Nature Medicine|August 24, 2004
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalTyler J Curiel, George Coukos, Linhua Zou, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancerSasha E Stanton, Denise L Cecil, Howard H Bailey, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.
Journal for Immunotherapy of Cancer|June 9, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancerMary L Disis, Sarah F Adams, Jyoti Bajpai, et al.
Cancer Research|April 5, 2017
Precancer Atlas to Drive Precision Prevention TrialsAvrum Spira, Matthew B Yurgelun, Ludmil Alexandrov, et al.
Cancer Immunology Research|August 14, 2014
Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinomaKelly G Paulson, Andrew Tegeder, Christoph Willmes, et al.
Pageof 19